Navigation Links
New Pills Show Promise for Hepatitis C
Date:1/3/2013

By Serena Gordon
HealthDay Reporter

WEDNESDAY, Jan. 2 (HealthDay News) -- Two new pills on the horizon for people with hepatitis C promise shorter treatment time and fewer side effects than today's standard treatment, interferon.

The first treatment studied combines a drug currently called ABT-450/r and one called ABT-333. Together, these drugs achieved up to a 95 percent sustained response, meaning the drugs suppressed levels of hepatitis C in the blood over time.

The second drug, called sofosbuvir, when combined with the currently used medication ribavirin, induced a 100 percent sustained response rate, the researchers found.

Both drugs require just 12 weeks of treatment compared to today's standard of 48 weeks, according to the authors.

"Over the next few years, we're going to have several new options to eradicate the hepatitis C virus," said the lead author of the ABT-450/r study, Dr. Fred Poordad, a professor of medicine at the University of Texas Health Science Center in San Antonio.

"We're hopeful that in the next 10 years, we should be able to eradicate hepatitis C in most Americans," said Poordad.

Both studies appear in the Jan. 3 issue of the New England Journal of Medicine. The ABT-450/r study was funded by the drug maker, Abbott Pharmaceuticals, and the sofosbuvir study was funded by drug makers Pharmasset and Gilead Sciences.

More than 3 million Americans have hepatitis C, a contagious liver disease usually spread through contact with the blood of someone already infected, according to the U.S. Centers for Disease Control and Prevention. The infection can be either acute or chronic. Chronic hepatitis C can scar the liver and eventually lead to liver failure. Poordad said it's one of the most common reasons for a liver transplant.

The current treatment combines two medications: interferon and ribavirin. Interferon is only available by injection, and must be administered three times a week for 48 weeks. Ribavirin is a pill. Side effects of interferon, which can last the duration of treatment, include flu-like symptoms, such as fever, chills, muscle aches and headache.

Poordad explained that this is because interferon dampens the whole immune system to keep the virus at bay. The new medications are what's called targeted therapies, which specifically go after the hepatitis C virus instead of attacking the whole immune system, he said.

"We're giving a drug that's killing the virus without bothering the host (the person with hepatitis C)," said Poordad.

His study had 50 people with genotype 1 hepatitis C, the most common and hardest-to-treat form of hepatitis C, according to Poordad. None had developed liver scarring (cirrhosis) yet.

Study volunteers were split into three groups. One group had never been treated for hepatitis C and received ABT-333, ribavirin and 250 milligrams (mg) of ABT-450 with 100 mg of ritonavir (making the ABT-450/r combination). The second group had also never received treatment. They received the same medications, except their dose of ABT-450 was 150 mg. The third group had received treatment for hepatitis C but had had no response or only a partial response to treatment. They were given ABT-333, ribavirin and 150 mg of ABT-450 and 100 mg of ritonavir.

The first two groups had a 95 percent and 93 percent sustained response to the drug. In the third group, only 47 percent had a sustained virologic response, the investigators found.

The most common side effects included abnormal liver function tests, fatigue, nausea, itching and headache.

The second study, conducted in New Zealand, included 95 people with hepatitis C genotypes 1, 2 or 3. They were split into eight groups and received varying treatments. All of the treatments included 400 mg of the new drug sofosbuvir.

Sustained response rates were impressive -- 100 percent -- when sofosbuvir was combined with ribavirin, or with interferon for people with genotypes 2 and 3. When sofosbuvir was given alone, it achieved a sustained response rate of 60 percent for those with genotypes 2 and 3.

For those with genotype 1 who had never received treatment, sofosbuvir and ribavirin achieved an 84 percent sustained response. For those who hadn't responded to prior treatment, this combination resulted in just a 10 percent sustained viral response rate.

Like ABT-450/r, the side effects for sofosbuvir included headache, fatigue, nausea and skin rash.

Experts welcomed the findings.

"Overall, these results are encouraging, and there's definitely a need for new treatments," said liver specialist Dr. Natasha Von Roenn, from Loyola University Medical Center in Chicago.

"Headache seemed to be a significant side effect in both studies, but the good news was that none of the patients had to stop treatment because of side effects," she noted.

"We're moving closer to having an oral interferon-free regimen with good response rates," she added.

Both studies were phase 2 studies, so neither treatment is yet available.

More information

Learn more about hepatitis C and its treatment from the U.S. Centers for Disease Control and Prevention.

SOURCES: Fred Poordad, M.D., professor of medicine, University of Texas Health Science Center, and chief medical officer, Alamo Medical Research, San Antonio, Texas; Natasha Von Roenn, M.D., hepatologist and assistant professor of medicine, Loyola University Medical Center, Chicago; Jan. 3, 2013, New England Journal of Medicine


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. People May Skip Generic Pills if Color Differs From Brand-Name Drug
2. Capsiplex Plus Reviews for Improved Weight Loss Supplement Added to BestAppetiteSuppressantPills.com
3. CB-1 Weight Gainer Commercial Sparks Conversation in Social Media World about the Weight Gain Pills
4. hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Adds Prescription Strength Saffron Extract Diet Pills to Their Exhaustive Product Line
5. US Drug Watchdog Now Urges Women Who Used Yaz or Yasmin Birth Control Pills and Had a Heart Attack or Stroke to Call The Johnson Law Group immediately-Get Identified Now
6. The US Drug Watchdog Now Urges Any Woman Who Used The Birth Control Pills Yaz Or Yasmin And Then Had A Heart Attack Or Stroke To Call The Johnson Law Group----ASAP
7. The US Drug Watchdog Now Urges Women Who Suffered A Heart Attack Or Stroke After Using Yaz Yasmin Birth Control Pills To Contact The Johnson Law Group Immediately
8. OB/GYNs Endorse Over-the-Counter Birth Control Pills
9. New Prep for Colon Screen Uses Four Pills, Not Liquid Laxative
10. The US Drug Watchdog Now Offers Women Who Had A Heart Attack Or Stroke After Using The Birth Control Pills Yaz Yasmin Birth Control Pills Get To The Best Attorneys
11. Danger at Home Lurks in Pills, Plants, Chemicals and More
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Pills Show Promise for Hepatitis C
(Date:4/25/2017)... ... April 25, 2017 , ... ... analytics to its patient care management module. Using this new feature, sleep physicians ... has been initiated on continuous positive airway pressure (CPAP), oral, or other forms ...
(Date:4/25/2017)... ... ... There is no better place in South Florida to undergo two common heart ... of Consumer Reports focused on heart health. , The magazine gave Memorial ... bypass and aortic valve replacement procedures. , Consumer Reports rated Memorial’s Cardiac ...
(Date:4/25/2017)... ... April 25, 2017 , ... Amendia, Inc., ... of its strategic partnership with and platinum sponsorship of Global Spine Outreach (“GSO”), ... and effective management of complex spine deformity cases, particularly in children. , GSO’s ...
(Date:4/24/2017)... ORLANDO, FLORIDA (PRWEB) , ... April 24, 2017 ... ... of telehealth technology yesterday, featuring Bring Your Own Device (BYOD) capabilities at Telehealth ... compliment LG CNS’ pre-packaged telehealth bundles, which pairs medical devices with a pre-programmed ...
(Date:4/24/2017)... , ... April 24, 2017 , ... The Santana Telehealth ... ATA 2017: Telehealth 2.0 — the American Telemedicine Association’s annual conference, on April 23 ... Project for using telemedicine to improve the lives of the poor and underserved in ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... Texas , April 20, 2017  Vivify Health, ... mobile devices, has been awarded a very significant patent ... via EMRs to continual care via digital health.  This ... key intellectual property and further secures Vivify,s position as ... launched in 2009, was the first company to apply ...
(Date:4/20/2017)... , April 20, 2017  RXi Pharmaceuticals Corporation ... therapeutics that address significant unmet medical needs, today ... the Company,s consumer product development program, based on ... Society for Investigative Dermatology (SID) 76 th ... and promote the sciences relevant to skin health ...
(Date:4/20/2017)... , April 20, 2017   ZappRx, Inc ., ... specialty drug prescribing process, today announced it closed $25 million ... a venture capital firm based in Seattle ... Qiming Venture Partners . The Series B round included participation ... round in 2014, and GV (formerly Google Ventures). ...
Breaking Medicine Technology: